Joseph McCracken
Director/Board Member at SAVARA INC.
Net worth: 994 701 $ as of 2024-03-30
Profile
Joseph S.
McCracken is currently serving as a Director at Alkahest, Inc., REGiMMUNE Corp., Neuropore Therapies, Inc., Savara, Inc., Modalis Therapeutics Corp., and Lumos Pharma, Inc. He previously held positions as a Director at NewLink Genetics Corp., Aravas, Inc., Calliditas Therapeutics Suisse SA, Kindred Biosciences, Inc., Nexvet Biopharma Plc, Nexvet Australia Pty Ltd., and Calliditas Therapeutics France SAS.
Additionally, he served as the Vice President of Business Development at Genentech, Inc. and Rhone-Poulenc Rorer SA. He also held the role of Vice President of Business Development at Aventis Pharmaceuticals, Inc. and General Manager at Roche Diagnostics KK.
McCracken has a diverse educational background, having obtained undergraduate, graduate, and doctorate degrees from The Ohio State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SAVARA, INC.
0.14% | 2023-12-13 | 190,837 ( 0.14% ) | 950 368 $ | 2024-03-30 |
LUMOS PHARMA, INC.
0.19% | 2024-02-29 | 15,721 ( 0.19% ) | 44 333 $ | 2024-03-30 |
Joseph McCracken active positions
| Companies | Position | Start |
|---|---|---|
| SAVARA INC. | Director/Board Member | 2017-04-26 |
| MODALIS THERAPEUTICS CORPORATION | Director/Board Member | 2018-07-31 |
| LUMOS PHARMA, INC. | Director/Board Member | 2020-03-22 |
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Director/Board Member | 2015-11-30 |
Neuropore Therapies, Inc.
 Neuropore Therapies, Inc. Medical/Nursing ServicesHealth Services Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA. | Director/Board Member | 2019-10-28 |
Alkahest, Inc.
 Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Director/Board Member | 2013-11-30 |
Former positions of Joseph McCracken
| Companies | Position | End |
|---|---|---|
| KINDRED BIOSCIENCES, INC. | Director/Board Member | 2021-08-26 |
| NEXVET BIOPHARMA PUBLIC LIMITED CO | Director/Board Member | 2017-07-30 |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Director/Board Member | - |
| ░░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Joseph McCracken
| The Ohio State University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| SAVARA INC. | Health Technology |
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| LUMOS PHARMA, INC. | Health Technology |
| Private companies | 16 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Aravas, Inc.
 Aravas, Inc. Pharmaceuticals: MajorHealth Technology Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX. | Health Technology |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Kindred Biosciences, Inc.
 Kindred Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA. | Health Technology |
Alkahest, Inc.
Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Health Technology |
Nexvet Biopharma Plc
 Nexvet Biopharma Plc Pharmaceuticals: MajorHealth Technology Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland. | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Roche Diagnostics KK
 Roche Diagnostics KK Medical SpecialtiesHealth Technology Part of Roche Holding AG, Roche Diagnostics KK is a Japanese company that manufactures and sells medical equipment. The private company is based in Tokyo, Japan. The company was founded in 1932. The CEO is Shin Ogasawara. | Health Technology |
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
| Rhone-Poulenc Rorer SA | |
Nexvet Australia Pty Ltd.
 Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Neuropore Therapies, Inc.
Neuropore Therapies, Inc. Medical/Nursing ServicesHealth Services Neuropore Therapies, Inc. provides biopharmaceutical services. It also offers alpha-synuclein (ASYN), amyloid beta, autophagy, and publications programs. The company was founded by Eliezer Masliah in 2008 and is headquartered in San Diego, CA. | Health Services |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
- Stock Market
- Insiders
- Joseph McCracken